SAN ANTONIO--(BUSINESS WIRE)--Prytime Medical Devices, Inc. announced that Andrew Holman has joined the company as Chief Commercialization Officer effective October 26, 2020.
Holman has more than 20 years of senior management experience, including strategic development and commercial execution in medical devices, most recently as Global President, Q Medical Devices. Prior to that, he served as Chief Commercial Officer at BrainScope, a neuro trauma technology start-up where he successfully commercialized a first-of-its kind medical device. Before BrainScope, Holman served as Chief Commercial Officer for Integer Holdings Corporation (formerly Greatbatch). He has a track record of success in driving revenue growth, profitability, and outstanding P&L management. He is also skilled at building best-in-class teams and maximizing sales force capabilities.
“Andrew is the right commercialization leader for Prytime,” said David Spencer, CEO Prytime. “Andrew’s extensive medical device background and market development skills will help position Prytime products as standard of care in trauma patients.”
“I am very excited to join the Prytime team,” said Andrew Holman. “I believe Prytime has state-of-the-art products and a talented team that uniquely positions it to capitalize in the trauma market while saving lives.”
Holman earned a BS Degree in Psychology & Business Administration from Rollins College, and has received extensive leadership training throughout his career.
About Prytime Medical Devices, Inc.
Prytime Medical Devices, Inc. designs, develops and commercializes minimally invasive solutions for hemorrhage control. The underlying intellectual property for the ER-REBOA™ Catheter was conceived by experienced military vascular surgeons Dr. Todd Rasmussen and Dr. Jonathan Eliason, based on lessons learned in combat trauma surgery. The successful transition to use in civilian trauma has contributed to product evolution which will contribute to saving even more lives.